Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Property, Plant & Equipment (Net)

Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026

Property, plant & equipment (net) falls 62.1% from a year ago

Property, plant & equipment (net) stood at $3.42M at the end of Q1 FY2026, down 62.1% from a year earlier and down 30.0% from the prior quarter.

Context

  • Property, plant & equipment (net) amounted to 0.9% of total assets at the end of Q1 FY2026, down 2.0 pp from a year earlier.
  • Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -62.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.42M-30.0% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoMar 2025
$9.02M-62.1% since
Property, Plant & Equipment (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-62.1%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Property, Plant & Equipment (Net) history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Property, Plant & Equipment (Net) vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's Mar 2026 property, plant & equipment (net) of $3.42M is the 6th highest of the 10 companies compared; the peer median is $3.97M.
  • Its year-over-year change of -62.1% is the lowest of 9, against a peer median of -23.6%.
  • Property, plant & equipment (net) amounts to 0.9% of total assets for AKBA, versus a peer median of 2.7%.
AKBA Competitors Peer median
Property, Plant & Equipment (Net) for AKBA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FDMT4D Molecular Therapeutics, Inc.Mar 2026$30.94M -20.9%-2.3%6.0%
KALVKalVista Pharmaceuticals, Inc.Dec 2025$12.86M ——3.8%
PRTAProthena Corporation plcMar 2026$9.35M -27.5%+8.6%2.7%
CMPXCompass Therapeutics, Inc.Mar 2026$8.92M +32.3%+26.6%4.3%
GOSSGossamer Bio, Inc.Mar 2026$3.97M -17.5%-24.9%3.1%
AKBAAkebia Therapeutics, Inc.Mar 2026$3.42M -62.1%—0.9%
ZVRAZevra Therapeutics, Inc.Mar 2026$1.52M -26.3%-1.5%0.5%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$1.03M -18.0%-25.6%0.4%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$921K -46.1%-33.9%0.2%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$785K -43.2%-30.9%0.2%
Peer median (excluding AKBA) $3.97M-23.6%-13.6%2.7%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents149.8M90.47M42.93M51.87M184.84M
Short-term Investments00000
Net Receivables51.58M40.28M39.29M34.37M47.03M
Inventory36.63M21.57M15.69M16.24M15.61M
Other Current Assets032.86M20.24M7.32M(62.64M)
Total Current Assets271.15M185.18M118.15M113.83M184.84M
Property, Plant & Equipment (Net)40.61M34.37M16.05M10.42M0
Goodwill59.04M59.04M59.04M59.04M59.04M
Intangible Assets108.13M72.08M36.04M00
Long-term Investments00000
Tax Assets00000
Other Non-current Assets50.42M5.37M12.42M37.38M132.68M
Total Non-current Assets258.2M170.87M123.55M106.84M191.72M
Total Assets529.35M356.05M241.7M220.67M376.57M
Account Payables33.59M18.02M14.64M15.18M21.19M
Short-term Debt97.54M32M19.55M4.31M40.08M
Tax Payables00000
Deferred Revenue20.91M3.74M000
Other Current Liabilities31.18M52.53M18.26M22.75M101.67M
Total Current Liabilities261.05M129.54M99.87M80.91M162.94M
Long-term Debt53.08M34.08M71.2M175.47M176.21M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)21.47M43.3M43.3M00
Other Non-current Liabilities86.03M114.95M48.98M9.93M4.8M
Total Non-current Liabilities194.29M221.29M172.42M188.94M181.02M
Total Liabilities455.34M350.82M272.29M269.86M343.96M
Common Stock1K2K2K2K2K
Retained Earnings(1.46B)(1.56B)(1.61B)(1.68B)(1.68B)
Accumulated OCI6K6K6K6K6K
Other Stockholders Equity000(0)0
Minority Interest00000
Total Equity74.01M5.23M(30.58M)(49.19M)32.61M
Total Debt189.13M99.78M104.18M188.73M216.3M
Net Debt39.33M9.32M61.26M136.86M31.45M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.